AbbVie is profitable, growing, and paying a rising dividend. CRISPR is burning cash in pursuit of a

Vertex Pharmaceuticals NASDAQ: VRTX is continuing to broaden its business beyond cystic fibrosis, wi

Vertex Pharmaceuticals NASDAQ: VRTX highlighted a series of upcoming clinical, regulatory and commer

Vertex Pharmaceuticals NASDAQ: VRTX outlined a broadening commercial and clinical strategy at the Ca

One company is scaling revenue rapidly but burning cash; the other is pioneering gene therapy with m

Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow

Vertex, Inc. (VERX) Presents at Goldman Sachs Communacopia + Technology Conference 2026 Transcript

Vertex Pharmaceuticals' core business is rock-solid, but it is also slowly expanding into new areas.

Vertex Pharmaceuticals is slowly but surely expanding beyond its highly successful core therapeutic

KING OF PRUSSIA, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), the Decision-to

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the succ

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced manageme

Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeli

Explore the exciting world of Vertex Pharmaceuticals (VRTX +1.44%) with our contributing expert anal

Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. How

Vertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area. The company

I was too cautious previously on Vertex Pharmaceuticals' prospects. Revenue from its cystic fibrosis

KING OF PRUSSIA, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the

Vertex Pharmaceuticals could face competition in its most important market by far. The company is pr

Vertex (VERX) could produce exceptional returns because of its solid growth attributes.

Gainers Corvex (NASDAQ:MOVE) stock moved upwards by 44.6% to $15.56 during Tuesday's regular se

DA Davidson analyst Lucky Schreiner maintains Vertex (NASDAQ:VERX) with a Neutral and lowers the

Vertex Inc (NASDAQ:VERX) reported strong Q2 earnings, exceeding analyst estimates. Sales for Q3 also

Stephens & Co. analyst Brett Huff maintains Vertex (NASDAQ:VERX) with a Overweight and lowers

Baird analyst Rob Oliver maintains Vertex (NASDAQ:VERX) with a Outperform and lowers the price ta

Vertex (NASDAQ:VERX) narrows FY2026 sales outlook from $823.500 million-$831.500 million to $825.000

Vertex (NASDAQ:VERX) reported quarterly earnings of $0.20 per share which beat the analyst consensus

Morgan Stanley analyst Chris Quintero downgrades Vertex (NASDAQ:VERX) from Overweight to Equal-We

TD Cowen analyst Jared Levine initiates coverage on Vertex (NASDAQ:VERX) with a Buy rating and an

Goldman Sachs sees a familiar pattern returning in 2026: prior-year laggards often beat the S&P

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings

U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are s

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin

U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Wednesday. Here are

Companies Reporting Before The Bell • Sony Group (NYSE:SONY) is estimated to report quarterly earni

Companies Reporting Before The Bell • Nomad Foods (NYSE:NOMD) is projected to report quarterly earn

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earn

Companies Reporting Before The Bell • GCM Grosvenor (NASDAQ:GCMG) is likely to report quarterly ear

Upgrades

  Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to repor

  On Tuesday, 951 companies hit new 52-week lows.